Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Mar 20, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 194 |
| CEO | John Butler |
Contact Details
Address: 245 First Street, Suite 1400 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 871 2098 |
| Website | akebia.com |
Stock Details
| Ticker Symbol | AKBA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001517022 |
| CUSIP Number | 00972D105 |
| ISIN Number | US00972D1054 |
| Employer ID | 20-8756903 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Butler MBA | Chief Executive Officer, President and Director |
| Erik John Ostrowski M.B.A. | Chief Business Officer, Senior Vice President, Chief Financial Officer and Treasurer |
| Dr. Steven Keith Burke M.D. | Senior Vice President and Chief Research and Development Officer |
| Nicholas Grund | Senior Vice President and Chief Commercial Officer |
| Richard C. Malabre | Senior Vice President and Chief Accounting Officer |
| Dr. Justin McCue Ph.D. | Senior Vice President and Chief Technology Officer |
| Mercedes Carrasco | Senior Director of Investor and Corporate Communications |
| Carolyn Rucci | Senior Vice President, Chief Legal Officer and Secretary |
| Meredith Bowman | Senior Vice President and Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Feb 2, 2026 | 144 | Filing |
| Feb 2, 2026 | 144 | Filing |
| Feb 2, 2026 | 144 | Filing |
| Feb 2, 2026 | 144 | Filing |